title: What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
authors.affiliation: The Toledo Hospital Family Practice Residency, Ohio, USA. john.mcconaghy.md@promedica.org
authors.forename: J R
authors.initials: JR
authors.lastname: McConaghy
mesh_terms: D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044383:Black People; D004311:Double-Blind Method; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006977:Hypertension, Renal / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000517:prevention & control*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D017257:Ramipril / Q000627:therapeutic use; D001741:Black or African American
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine; D008790:Metoprolol; D017257:Ramipril